Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500080 | 0.94 | CCR8 (0.50) | APPCCR8ACHEBCHE | |
| SCHEMBL6496812 | 0.92 | BCHE (0.55) | APPACHEBCHENR1H3 | |
| SCHEMBL6498806 | 0.92 | ACHE (0.50) | APPACHEBCHE | |
| SCHEMBL6505559 | 0.91 | EPHX2 (0.56) | APPACKR3LTA4HEPHX2BCHE | |
| SCHEMBL6503460 | 0.88 | SIGMAR1 (0.52) | APPACKR3 | |
| SCHEMBL6498983 | 0.86 | APP (0.49) | APPACHE | |
| SCHEMBL6506745 | 0.86 | ATM (0.48) | APPACHEHCRTR2RAB9A | |
| SCHEMBL6508928 | 0.85 | GAA (0.62) | APPACHEBCHE | |
| SCHEMBL6503729 | 0.85 | EPHX2 (0.58) | LTA4HEPHX2ACHEBCHERAB9A | |
| SCHEMBL6507792 | 0.83 | MTNR1A (0.51) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | APP 1930/4885ACKR3 17/4885LTA4H 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.